Microbiotica

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

https://www.microbiotica.com/

11-50 employees

Growth Trajectory

Microbiotica has strong growth potential through advancing its pipeline of LBPs, expanding clinical trials internationally, and pursuing partnerships for manufacturing and clinical trials. Their focus on precision microbiome medicines and collaborations with research institutions positions them well for future expansion. The company also aims to address the unmet needs in melanoma treatment by identifying bacterial strains that enhance ICI response.

Technical Challenges

Ensuring the bacterial strains in MB310 and MB097 successfully engraft into patients’ intestinal microbial community.

Scaling up LBP production for clinical trials and potential commercialization.

Improving manufacturing processes for LBPs

Maintaining viability and stability of bacteria during manufacturing and storage.

Tech Stack

Metagenomic sequencingBioinformaticsLyophilisationLive biotherapeutic products (LBPs)Precision Metagenomics PlatformCloudflare Bot ManagementDefined bacterial consortiaMicrobiome profiling platform

Team Size

Scientific Advisory Board

Clinical trial teams

LBP manufacturing and development teams

Key Risks

Clinical trial failures could significantly impact product development and investor confidence.

Regulatory hurdles for live biotherapeutic products (LBPs) may delay or prevent market entry.

Competition from other companies developing immunotherapies and microbiome-based therapeutics could erode market share.

Ensuring the bacterial strains in their LBPs successfully engraft and thrive in patients’ intestinal microbial community presents a technical challenge.

Market acceptance of microbiome-based therapies may be slower than anticipated.

Opportunities

Leverage their proprietary microbiome profiling platform to identify new bacterial targets and develop innovative LBPs.

Expand clinical trials to new regions and indications beyond immuno-oncology and inflammatory bowel disease.

Form strategic partnerships with pharmaceutical companies to co-develop and commercialize their LBPs.

Capitalize on the growing interest in microbiome-based therapies to attract investment and talent.

Address the unmet need for effective treatments for melanoma patients resistant to immunotherapies.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes